Vertaling van "parties have access to such information " (Nederlands → Frans) :

The FAMHP and the BUM department in particular ensures that all parties have access to such information, so that medicines can be used rationally and safely.
The FAMHP and the BUM department in particular ensures that all parties have access to such information, so that medicines can be used rationally and safely.

To promote the proper use of a medicine, all relevant parties need to have objective, appropriate, up-todate and readily accessible information.
To promote the proper use of a medicine, all relevant parties need to have objective, appropriate, up-todate and readily accessible information.

In concrete terms, this means that out of a hundred individuals who suffer from a mental disorder, 33 seek professional help, whereas only 27 really do receive treatment. […] The fact that between 6 and 8 out of 10 of those who suffer from a mental disorder do not receive treatment suggests that the access to mental health care is littered with stumbling blocks that have an inhibiting effect, such as the attitude towards mental health, the availability of medical care, financial considerations or the extent to which individuals think they need help”. ) (Bruffaerts et al., 2004) 14
Concrètement, cela signifie que parmi 100 personnes qui souffrent d’un trouble mental, 33 demandent une assistance professionnelle et seules 27 reçoivent effectivement un traitement.[…] Le fait que 6 à 8 personne sur 10 souffrant d’un trouble mental ne reçoivent pas de traitement indique que l’accès aux soins de santé mentale est parsemé d’embûches qui exercent un effet inhibiteur, comme l’attitude vis-à-vis de la santé mentale, l’accessibilité aux soins, des

This release contains forward-looking information about an agreement by Pfizer to acquire FoldRx, and about FoldRx’s product candidate tafamidis, its other clinical and preclinical development programs and its technology platform, including their potential benefits, that involves substantial risks and uncertainties. Such risks and uncertainties include, among other things, the satisfaction of conditions to closing the agreement; the uncertainties inherent in research and development; whether and when a new drug application for tafamidis will be filed with the FDA; decisions by regulatory authorities regarding whether and when to approve any drug applications that have been or may be filed for tafamidis and that may be filed for any other product candidates that may be generated by FoldRx’s technology platform as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of tafamidis and such other product candidates; and competitive developments. A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2009 and in its reports on Form 10-Q and Form 8-K.
Such risks and uncertainties include, among other things, the satisfaction of conditions to closing the agreement; the uncertainties inherent in research and development; whether and when a new drug application for tafamidis will be filed with the FDA; decisions by regulatory authorities regarding whether and when to approve any drug applications that have been or may be filed for tafamidis and that may be filed for any other product candidates that may be generated by FoldRx’s technology platform as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of tafamidis and such other product candidates; and competitive developments.